T-Therapeutics Ltd
Mike Jenns has a diverse work experience in the field of biotechnology. Mike is currently working as an Associate Director of Cell Line Development/CMC at T-Therapeutics Ltd since 2023. Prior to this, they held various roles at Kymab Ltd, including Associate Director of Cell Line Development, Group Leader of Cell Line Development, and Senior Research Scientist from 2017 to 2023. Before joining Kymab Ltd, Mike worked at MedImmune as an R&D Manager and Scientist I from 2009 to 2017. Mike started their career as a Research Scientist at UCB Pharma in 2005 and worked there until 2009. Mike's early experience includes working as a Research Assistant at PowderMed from 2002 to 2005.
Mike Jenns attended Oxford Brookes University from 1999 to 2001, where they pursued a Bachelor of Science degree in Cell and Molecular Biology.
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.